Research Assistant
London, England, United Kingdom
Around one year following the advent of COVID-19, the disease arising from the SARS-CoV-2 virus, I began to study people's adaptive immune responses to this virus. In the adept and welcoming team of Dr Katie Doores, we measured the serum antibody responses in patients infected with, or vaccinated against, SARS-CoV2. We characterised the neutralising capacity of patient serum against the panoply of variants springing up at the time. We also worked to identify individual potently-neutralising antibodies from patients' memory B cells, gleaning therapeutic candidates against the virus. I wrote about my experiences in an entry for Nature Microbiology's 'Behind the Paper' blog.